Search research articles
Contact Us
Filters
Showing results (181-190 of 193) with videos related to
Page
of 20
Sort By:
Blood Advances
|
September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Gerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood
|
October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood Advances
|
May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse
Niek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood Cancer Journal
|
June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Jacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2024
Risk Stratification in Older Intensively Treated Patients With AML
Jurjen Versluis, Marlen Metzner, Ariel Wang, et al.
Haematologica
|
April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Haematologica
|
June 24, 2009
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
Arjan A van de Loosdrecht, Canan Alhan, Marie Christine Béné, et al.
Cancer Cell
|
August 19, 2014
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
Matthew S Zabriskie, Christopher A Eide, Srinivas K Tantravahi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Monique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Blood
|
November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 193) with videos related to
Sort By:
Page
of 20
Blood Advances
|
September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Gerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood
|
October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood Advances
|
May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse
Niek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood Cancer Journal
|
June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Jacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2024
Risk Stratification in Older Intensively Treated Patients With AML
Jurjen Versluis, Marlen Metzner, Ariel Wang, et al.
Haematologica
|
April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Haematologica
|
June 24, 2009
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
Arjan A van de Loosdrecht, Canan Alhan, Marie Christine Béné, et al.
Cancer Cell
|
August 19, 2014
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
Matthew S Zabriskie, Christopher A Eide, Srinivas K Tantravahi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Monique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Blood
|
November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Page
of 20